Kyverna Therapeutics Files 8-K
Ticker: KYTX · Form: 8-K · Filed: Oct 29, 2025 · CIK: 1994702
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
TL;DR
Kyverna filed a routine 8-K, no major news.
AI Summary
Kyverna Therapeutics, Inc. filed an 8-K on October 29, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond routine reporting requirements.
Why It Matters
This 8-K filing indicates routine corporate reporting by Kyverna Therapeutics, Inc. to the SEC, without disclosing new material events.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for routine disclosures and does not contain information that suggests an immediate change in risk for investors.
Key Players & Entities
- Kyverna Therapeutics, Inc. (company) — Registrant
- October 29, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 5980 Horton St., Suite 550, Emeryville, California 94608 (address) — Principal Executive Offices
- (510) 925-2492 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing for Kyverna Therapeutics, Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on October 29, 2025.
In which state is Kyverna Therapeutics, Inc. incorporated?
Kyverna Therapeutics, Inc. is incorporated in Delaware.
What is the address of Kyverna Therapeutics, Inc.'s principal executive offices?
The address of Kyverna Therapeutics, Inc.'s principal executive offices is 5980 Horton St., Suite 550, Emeryville, California 94608.
Does this filing disclose any specific new financial results or material events?
No, this filing appears to be for routine disclosures and does not specify any new financial results or material events.
Filing Stats: 545 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-10-29 06:32:20
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share KYTX The Nasdaq Stock Mar
Filing Documents
- d80007d8k.htm (8-K) — 24KB
- d80007dex991.htm (EX-99.1) — 28KB
- 0001193125-25-254571.txt ( ) — 176KB
- kytx-20251029.xsd (EX-101.SCH) — 3KB
- kytx-20251029_lab.xml (EX-101.LAB) — 18KB
- kytx-20251029_pre.xml (EX-101.PRE) — 11KB
- d80007d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KYVERNA THERAPEUTICS, INC. Date: October 29, 2025 By: /s/ Marc Grasso Marc Grasso Chief Financial Officer